8.16
+0(+0.00%)
Currency In USD
Address
4224 Campus Point Court
San Diego, CA 92121
United States of America
Phone
858 202 6300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
34
First IPO Date
October 09, 2012
| Name | Title | Pay | Year Born |
| Mr. Joseph P. Hagan M.B.A. | Chief Executive Officer & Director | 1.06M | 1969 |
| Mr. Christopher Ray Aker J.D. | Senior Vice President, General Counsel & Corporate Secretary | 575,942 | 1961 |
| Ms. Crispina Calsada CPA | Chief Financial Officer | 669,100 | 1970 |
| Dr. Preston S. Klassen M.D., M.H.S. | President, Head of Research & Development and Director | 760,760 | 1969 |
| Dr. Rekha Garg M.D., M.S. | Chief Medical Officer | 0 | N/A |
| Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Senior Vice President of Clinical Operations | 0 | N/A |
| Mr. Daniel J. Penksa | Vice President of Finance & Controller | 0 | 1986 |
| Mr. Edmund Lee Ph.D. | Vice President of Translational Medicine | 0 | N/A |
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.